Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB122 + TAS-102 + ramucirumab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AB122 + TAS-102 + ramucirumab is an investigational three-drug combination being studied for oncology indications, most notably advanced solid tumors. - **AB122** is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor, classified as an immune checkpoint inhibitor (PD-1 inhibitor) and is under investigation for multiple cancers. - **TAS-102** is an oral combination chemotherapeutic consisting of trifluridine (a nucleoside analog) and tipiracil (a thymidine phosphorylase inhibitor) approved for metastatic colorectal cancer and studied in other malignancies. - **Ramucirumab** is a fully human monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, and is approved as monotherapy or combination therapy in gastric, gastroesophageal junction, colorectal, non-small cell lung, and hepatocellular cancers[2][1][3][5]. This regimen is being evaluated for synergistic activity by combining immune checkpoint blockade, cytotoxic chemotherapy, and antiangiogenic therapy.
- Brand names
- Cyramza
- Other names
- AB122 + TAS-102 + ramucirumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on AB122 + TAS-102 + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB122 + TAS-102 + ramucirumab.